SillaJen: first to use lab-grown human tissue to find best cancer drug dose

Q: How long will it take to read this news story?

The story "SillaJen: first to use lab-grown human tissue to find best cancer drug dose" has 588 words across 25 sentences, which will take approximately 3 - 5 minutes for the average person to read.

Q: Which news outlet covered this story?

The story "SillaJen: first to use lab-grown human tissue to find best cancer drug dose" was covered 5 hours ago by Korea Economic Daily, a news publisher based in South Korea.

Q: How trustworthy is 'Korea Economic Daily' news outlet?

Korea Economic Daily is a fully independent (privately-owned) news outlet established in 1964 that covers mostly economy news. The outlet is headquartered in South Korea and publishes an average of 8 news stories per day. It's most recent story was published 9 hours ago.

Q: What do people currently think of this news story?

The sentiment for this story is currently Negative, indicating that people regard this as "bad news".

Q: How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.<ul><li>News ID: #27149383</li><li>URL: https://beamstart.com/news/sillajen-first-to-use-lab-17423021285316</li></ul>

Korea Economic Daily Logo Korea Economic Daily 5h ago

SillaJen: first to use lab-grown human tissue to find best cancer drug dose - Korea Economic Daily

Quick Summary:

The company recently said it will apply for regulatory approval in Korea and the US in the second quarter to test a combination of its cancer drug candidate, BAL0891, with immunotherapy drug Tebimbra (tislelizumab).“We will determine the best dose for phase 2 trials based on data we obtained from earlier patient studies and new findings from our organoid models,” said a SillaJen official.

SillaJen plans to present additional findings at the American Association for Cancer Research (AACR) annual meeting in Chicago next month.“Based on our research with Qureator, we will move forward with clinical trials combining BAL0891 with Tebimbra, an immunotherapy similar to Keytruda,” said a SillaJen official.

Qureator has been testing BAL0891 in combination with Keytruda, a PD-1 inhibitor used in cancer immunotherapy, in organoid models of triple-negative breast cancer (TNBC), renal cell carcinoma (RCC), gastric cancer (GC) and colorectal cancer (CRC).